PMID- 33187089 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201201 IS - 2076-3921 (Print) IS - 2076-3921 (Electronic) IS - 2076-3921 (Linking) VI - 9 IP - 11 DP - 2020 Nov 11 TI - Resveratrol Improves Heart Function by Moderating Inflammatory Processes in Patients with Systolic Heart Failure. LID - 10.3390/antiox9111108 [doi] LID - 1108 AB - The effects of resveratrol (RES) in heart failure have already been evaluated in animal models; however, in human clinical trials, they have not been confirmed yet. The aim of this study was to assess the effects of resveratrol treatment in systolic heart failure patients (heart failure with reduced ejection fraction or HFrEF). In this human clinical trial, 60 outpatients with NYHA (New York Heart Association) class II-III HFrEF were enrolled and randomized into two groups: receiving either 100-mg resveratrol daily or placebo for three months. At the beginning and at the end of the study echocardiography, a six-minute walk test, spirometry, quality of life questionnaire, lab test and RNA profile analysis were performed. The systolic and diastolic left ventricular function, as well as the global longitudinal strain, were improved significantly in the resveratrol-treated group (RES). Exercise capacity, ventilation parameters and quality of life also improved significantly in the RES group. In parallel, the cardiac biomarker levels (N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and galectin-3) decreased in the treated group. The level of inflammatory cytokines decreased significantly after RES supplementation, as a consequence of the decreased expression level of leucocyte electron transport chain proteins. The main findings of our trial are that RES treatment added to the standard heart failure therapy improved heart function and the clinical condition by moderating the inflammatory processes in patients with HFrEF. FAU - Gal, Roland AU - Gal R AUID- ORCID: 0000-0003-4029-7913 AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Deres, Laszlo AU - Deres L AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. AD - HAS-UP Nuclear-Mitochondrial Interactions Research Group, 1007 Budapest, Hungary. FAU - Horvath, Orsolya AU - Horvath O AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Eros, Krisztian AU - Eros K AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. AD - HAS-UP Nuclear-Mitochondrial Interactions Research Group, 1007 Budapest, Hungary. AD - Department of Biochemistry and Medical Chemistry, Medical School, University of Pecs, 7602 Pecs, Hungary. FAU - Sandor, Barbara AU - Sandor B AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Urban, Peter AU - Urban P AUID- ORCID: 0000-0003-4043-3428 AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Soos, Szilvia AU - Soos S AD - Division of Pulmonology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. FAU - Marton, Zsolt AU - Marton Z AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Sumegi, Balazs AU - Sumegi B AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. AD - HAS-UP Nuclear-Mitochondrial Interactions Research Group, 1007 Budapest, Hungary. AD - Department of Biochemistry and Medical Chemistry, Medical School, University of Pecs, 7602 Pecs, Hungary. FAU - Toth, Kalman AU - Toth K AUID- ORCID: 0000-0002-0114-5231 AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Habon, Tamas AU - Habon T AUID- ORCID: 0000-0002-4816-857X AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. FAU - Halmosi, Robert AU - Halmosi R AUID- ORCID: 0000-0002-6965-7743 AD - Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7602 Pecs, Hungary. AD - Szentagothai Research Centre, University of Pecs, 7602 Pecs, Hungary. LA - eng GR - GINOP 2.3.2-15-2016-00048/Economic Development and Innovation Operative Programme Grant/ GR - TUDFO/47138/2019-ITM/Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary, within the framework of the 1st thematic programme of the University of Pecs/ PT - Journal Article DEP - 20201111 PL - Switzerland TA - Antioxidants (Basel) JT - Antioxidants (Basel, Switzerland) JID - 101668981 PMC - PMC7696241 OTO - NOTNLM OT - echocardiography OT - heart failure OT - inflammation OT - oxidative stress OT - resveratrol COIS- The authors declare no conflict of interest. EDAT- 2020/11/15 06:00 MHDA- 2020/11/15 06:01 PMCR- 2020/11/11 CRDT- 2020/11/14 01:03 PHST- 2020/10/08 00:00 [received] PHST- 2020/11/06 00:00 [revised] PHST- 2020/11/09 00:00 [accepted] PHST- 2020/11/14 01:03 [entrez] PHST- 2020/11/15 06:00 [pubmed] PHST- 2020/11/15 06:01 [medline] PHST- 2020/11/11 00:00 [pmc-release] AID - antiox9111108 [pii] AID - antioxidants-09-01108 [pii] AID - 10.3390/antiox9111108 [doi] PST - epublish SO - Antioxidants (Basel). 2020 Nov 11;9(11):1108. doi: 10.3390/antiox9111108.